InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Dec 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financials
TL;DR
InMed Pharma filed an 8-K on 12/15 for events on 12/12. Check for updates.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on December 15, 2025, reporting on events that occurred on December 12, 2025. The filing pertains to 'Other Events' and 'Financial Statements and Exhibits'. The company is incorporated in British Columbia and its principal executive offices are located in Vancouver, Canada.
Why It Matters
This 8-K filing indicates that InMed Pharmaceuticals Inc. has made a regulatory submission to the SEC, which may contain important updates regarding the company's operations or financial status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' and does not appear to disclose any immediate material adverse information.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- December 12, 2025 (date) — Earliest event reported
- December 15, 2025 (date) — Date of report
- Vancouver, B.C. Canada (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by InMed Pharmaceuticals Inc. in this 8-K filing?
The provided text does not detail the specific 'Other Events' but indicates that this item is covered in the filing.
What is the significance of the 'Financial Statements and Exhibits' being listed as an item in this 8-K?
This indicates that the filing includes financial information or exhibits, which could provide insights into the company's financial health or operational status.
When was InMed Pharmaceuticals Inc. incorporated, and where are its principal executive offices located?
InMed Pharmaceuticals Inc. was incorporated in British Columbia, and its principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada V6C 3E8.
What is the Commission File Number and IRS Employer Identification Number for InMed Pharmaceuticals Inc.?
The Commission File Number is 001-39685, and the IRS Employer Identification No. is 98-1428279.
What is the standard industrial classification for InMed Pharmaceuticals Inc.?
The Standard Industrial Classification for InMed Pharmaceuticals Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-12-15 09:32:30
Filing Documents
- ea0269687-8k_inmed.htm (8-K) — 26KB
- ea026968701ex99-1_inmed.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-25-121497.txt ( ) — 225KB
- inm-20251212.xsd (EX-101.SCH) — 3KB
- inm-20251212_lab.xml (EX-101.LAB) — 33KB
- inm-20251212_pre.xml (EX-101.PRE) — 22KB
- ea0269687-8k_inmed_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 12, 2025, the Company issued a news release related to the potential impact of H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" that was recently signed into law in the United States on BayMedica Inc., a subsidiary of the Company, and. A copy of the news release is attached to this Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The news release contains forward-looking information and includes a cautionary note regarding such forward-looking information identifying important factors that could cause actual results to differ materially from those in the forward-looking information.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated December 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: December 12, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2